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Elevated levels of circulating lipids are the major cause of cardiovascular disease, but beneficial outcomes
might be realized by targeting lipid carriers. Two papers in this issue of Cell Metabolism (So et al., 2012;
Wang et al., 2012) demonstrate how modulation of one arm of the unfolded protein response can decrease
plasma levels of VLDL particles and their associated lipids.The spotlight has long been trained on
low-density lipoproteins (LDLs) as the
major causative risk factor for atheroscle-
rosis. LDL particles are formed by modifi-
cation of very-low-density lipoproteins
(VLDLs) after their secretion from the liver.
A key protein component of both VLDL
and LDL particles is apolipoprotein B
(apoB), which is subject to co- and post-
translational degradation and is a scaffold
for the incorporation of lipids into these
particles (Brodsky and Fisher, 2008). The
number and composition of VLDL parti-
cles—and, thus, plasma triacyglycerol
(TG) and cholesterol levels—can be regu-
lated by multiple pathways, including the
unfolded protein response (UPR). In this
issue of Cell Metabolism, two papers
report on the manner in which the UPR
regulates plasma lipids and hepatic
VLDL production (So et al., 2012; Wang
et al., 2012). While the research teams
agree that IRE1a and XBP1, two UPR
regulators, play critical roles in regulating
plasma levels of TG and cholesterol,
each found distinct mechanisms that
lead to the UPR-dependent regulation of
VLDL biogenesis.
The UPR is triggered when the concen-
tration of aberrant proteins rises in the
endoplasmic reticulum (ER), and a tran-
scription factor, XBP1, plays a key role
in UPR signaling. Upon UPR induction,
the XBP1message is spliced, which leads
to the production of XBP1s and the
translation of the encoded transcription
factor whose products mitigate ER stress.
XBP1 splicing is catalyzed by an ER trans-
membrane protein known as IRE1a. Thefinding that mice lacking XBP1 exhibited
reduced levels of TGs and cholesterol
(Lee et al., 2008) suggested a link
between UPR signaling in the liver and
lipid metabolism. Lee et al. showed
that XBP1 regulates hepatic lipogenesis
via the induction of enzymes involved
in fatty acid synthesis, so that the
decrease in XBP1 function consequently
decreased lipid production. Based on
these and related findings, the UPR has
been invoked as a therapeutic target
to reduce plasma lipids, but before this
can be accomplished the finer details
underlying UPR-mediated effects on
lipid/lipoprotein metabolism need to be
established.
The web of evidence spun in Wang
et al. (2012) ensnares microsomal triglyc-
eride transfer protein (MTP) as the main
culprit in the UPR-mediated effect on
VLDL. MTP is an ER-resident protein
that recruits newly synthesized lipids or
lipids derived from cytosolic droplets
and transfers these molecules onto
apoB, an event that represents the first
step during VLDL assembly (Fisher and
Ginsberg, 2002). The lipid transfer activity
of MTP is maximal when the M subunit
forms a noncovalent heterodimer with
protein disulfide isomerase (PDI), which
also catalyzes the formation and rear-
rangement of disulfide bonds on nascent
secreted proteins. PDI, in turn, is a down-
stream target of the IRE1a-XBP1 axis.
When IRE1a was deleted, the authors
observed decreased secretion of TG-
rich VLDL both in vitro and in vivo. XBP1
was an intermediate in this pathwayCell Metabolism 1because XBP1s expression restored TG
secretion in IRE1a-deficient hepatocytes.
The authors traced the hypolipidemic
effect to impaired partitioning of lipids
into the ER lumen because of decreased
MTP function and PDI downregulation.
These data are in line with a report indi-
cating that IRE1b, an intestinal IRE1 iso-
form, regulates MTP levels in mice and
cell culture (Iqbal et al., 2008), and argue
for therapeutically targeting IRE1a for
hyperlipidemia.
In the other paper (So et al., 2012), the
authors build upon their previous
discovery that XBP1 deficiency results in
feedback activation of IRE1a (Lee et al.,
2008). As noted above, the XBP1
message is spliced by IRE1a, but IRE1a
possesses a second activity that leads
to ‘‘regulated IRE1-dependent decay’’
(RIDD) (Hollien and Weissman, 2006).
When the UPR is activated, IRE1 also
exhibits more promiscuous substrate
specificity and can clip any ER-associ-
ated mRNA. Therefore, RIDD alleviates
ER stress, since most ER-targeted
mRNAs encode for proteins that enter
the secretory pathway. To investigate
whether the RIDD pathway contributes
to the IRE1a-mediated effect on plasma
lipids, the authors performed amicroarray
analysis and found that IRE1a/RIDD
targets included messages encoding
proteins linked to lipid and lipoprotein
biogenesis. Of particular interest were
carboxyesterase 1 family members,
such as TG and cholesterol ester hydro-
lases, and angiopoietin-like protein 3,
which inhibits lipoprotein and endothelial6, October 3, 2012 ª2012 Elsevier Inc. 407
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Previewslipases. Importantly, these proteins had
been previously implicated in regulating
the plasma levels of lipids associated
with VLDL particles. These data then set
the stage for the authors to examine
whether XBP1 knockout or ablation via
silencing depresses the levels of plasma
lipids. As hypothesized, decreased
plasma TG and cholesterol were evident
when XBP1 was absent. XBP1 deficiency
also protected against hyperlipidemia in
dyslipidemic mice. Based on these
results, the authors propose XBP1 as a
therapeutic target to reduce plasma lipid
levels.
Together, the companion papers pin-
point the IRE1-XBP1 arm of the UPR as
a target to suppress the production of
circulating atherosclerosis-causing lipids,
a goal that will ultimately affect a disease
that results in one-quarter of all deaths in
the United States. However, enthusiasm
for this approach needs to be calibrated
by potential adverse effects on one or
more of the many targets of this pathway
and by questions that arise from some of
the disparate results in these studies.
Most notably, in So et al. there was408 Cell Metabolism 16, October 3, 2012 ª20decreased lipogenesis and protection
from steatosis in mice that were either
insulin resistant or fed a lipogenic diet,
but in Wang et al. there was mild steatosis
even in chow-fed mice, which was
exacerbated by a lipogenic diet. It is
unclear why Wang et al. (2012) did not
observe the decrease in lipogenesis
reported in So et al. (2012) and Lee et al.
(2008). This discrepancy will need to be
resolved experimentally before clinical
extensions can be contemplated, given
that an agent that reduces plasma lipid
levels while concurrently promoting
steatosis is unlikely to gain U.S. Food
and Drug Administration approval. More
fundamentally, it will be interesting to
pursue why neither study found adverse
effects on general protein production
by the liver despite the loss of this one
arm of the UPR, which is a key quality
control process in the ER for secretory
proteins. Nonetheless, by identifying
components of the UPR pathway that
regulate the composition and plasma
levels of VLDL lipids, these reports
provide a wealth of provocative informa-
tion that will enliven the field of lipoprotein12 Elsevier Inc.metabolism from both basic science and
therapeutic perspectives.ACKNOWLEDGMENTS
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Recent research suggests that obesitymay be influenced not only by dietary and genetic risk factors, but also
by the trillions of microorganisms inhabiting our gastrointestinal tract. Consistent with this notion, Cho et al.
(2012) use mice to demonstrate that subtherapeutic antibiotic treatment promotes adiposity.Humans and other mammals have co-
evolved with trillions of microorganisms
that thrive in and on our bodies. The
ensuing host-microbial interactions are
often beneficial; however, disturbance
of this delicate balance is thought to
lead to an increased risk of disease
(Dethlefsen et al., 2007). Recent efforts
have extensively characterized the com-
position of the microbial communities
found in multiple body habitats (Consor-tium, 2012), but we are only just begin-
ning to discover the unintended conse-
quences of a Western lifestyle on our
microbial partners (Blaser and Falkow,
2009). In particular, orally administered
broad-spectrum antibiotics have a clear
potential to influence the microbes inhab-
iting our gastrointestinal tract (the gut
microbiota).
But what are the functional conse-
quences of the widespread use of antibi-otics? One possible ramification is altered
host energy balance. A number of studies
have linked the gut microbiota to
obesity (Ba¨ckhed et al., 2004; Turnbaugh
et al., 2006), and low-dose antibiotics
have been used for decades to enhance
growth and feed efficiency in farm
animals (Jukes, 1971). The mechanisms
through which antibiotics promote this
phenomenon and whether the increasing
use of antibiotics in children contributes
